ABCC13 (Gene)

Entrez:150000

Description:ATP binding cassette subfamily C member 13 (pseudogene)

This gene is a member of the superfamily of genes encoding ATP-binding cassette (ABC) transporters. ABC proteins transport various molecules across extra- and intra-cellular membranes. ABC genes are divided into seven distinct subfamilies (ABC1, MDR/TAP, MRP, ALD, OABP, GCN20, and White). This family member is part of the MRP subfamily, which is involved in multi-drug resistance, but the human locus is now thought to be a pseudogene incapable of encoding a functional ABC protein. Alternative splicing results in multiple transcript variants; however, not all variants have been fully described. [provided by RefSeq, Jul 2008]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View ABCC13's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with ABCC13.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using ABCC13.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for ABCC13.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with ABCC13.

Results found

Linked to

	Label	Description
	GSE189035 inositol 2 v 4 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE169617 azacitidine 1 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE238116 EGR1 HCC overexpression MHCC97-H PLC-PRF-5 3 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE56010 adenosine 4 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE216043 cisplatin 3 v 9 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE111247 temozolomide LN-308 0 v 8 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE207514 GSE207515 PI3K inhibition 0 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE173116 GSE173118 ML-7 4 v 7 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE103567 EZH2 inhibition 5 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE182150 KIT LSD1 MYC inhibition 4 v 7 human dn Gene Set (Entity type)	A Gene Set from LINCS

GSE189035 inositol 2 v 4 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE169617 azacitidine 1 v 2 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE238116 EGR1 HCC overexpression MHCC97-H PLC-PRF-5 3 v 0 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE56010 adenosine 4 v 1 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE216043 cisplatin 3 v 9 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE111247 temozolomide LN-308 0 v 8 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE207514 GSE207515 PI3K inhibition 0 v 3 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE173116 GSE173118 ML-7 4 v 7 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE103567 EZH2 inhibition 5 v 2 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE182150 KIT LSD1 MYC inhibition 4 v 7 human dn

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.